1.Median Effective Dose of Ciprofol Combined with Sufentanil for Gastroscope in Different Populations
Min PAN ; Zhengda FAN ; Xiaoming ZUO ; Cheng WANG ; Jing MA ; Weibin XIE
Chinese Journal of Modern Applied Pharmacy 2024;41(12):1717-1722
OBJECTIVE
To test and compare the median effective dose(ED50) of ciprofol for gastroscope in patients of different genders and ages.
METHODS
Patients who planed to undergo gastroscope examination and treatment from March 2023 to April 2023 were selected, and divided into four groups according to stratified random method: N1 group(non-elderly male patients), N2 group(non-elderly female patients), N3 group(elderly male patients), and N4 group(elderly female patients). All patients received intravenous injection of 0.1 μg·kg−1 sufentanil followed by injection of the test dose of ciprofol according to Dixon’s modified sequential method. Gastroscope was performed after the disappearance of the eyelash reflex. The initial dose of ciprofol in all four groups was 0.4 mg·kg−1, and the ratio of adjacent doses was 1∶1.1. The next patient would receive a 10% increase in the dose of ciprofol if the patient experienced positive reactions such as coughing, frowning, and body movements during the endoscopy process. Otherwise, it would be judged as a negative reaction, and the next patient would receive a 10% decrease in the dose of ciprofol. The transition from a positive reaction to a negative reaction was defined as a turning point, and the study was terminated when seven turning points occurred. Hemodynamic parameters, oxygen saturation and adverse reactions were recorded at different time points. The Probit regression analysis method was used to calculate the ED50 of ciprofol for four groups.
RESULTS
The ED50 of ciprofol combined with 0.1 μg·kg−1 sufentanil for gastroscope in the non-elderly men, non-elderly women, elderly men, and elderly women were 0.409, 0.373, 0.356, 0.327 mg·kg−1, respectively. The ED50 of ciprofol in the N1 group was significantly higher compared with the N2 group and N3 group(P<0.05). The ED50 of ciprofol in the N4 group was significantly lower compared with the N2 group and N3 group(P<0.05).
CONCLUSION
The ED50 of ciprofol is significantly different among gastroscope patients of different genders and ages, which is lower in female patients than in male patients, and is lower in older patients than in non-elderly patients.
2.Effects of Huang'e Capsules on type IIIA prostatitis and inflammatory cytokines in the expressed prostatic secretion of the patient.
Yang-Fan OU ; Yu-Ru LIANG ; Pan XU ; Wen-Bin HUANG ; Zuo-Gang XIE
National Journal of Andrology 2024;30(12):1135-1140
OBJECTIVE:
To investigate the clinical efficacy of Huang'e Capsules in the treatment of type ⅢA chronic prostatitis, and its effects on the levels of the inflammatory cytokines neutrophil elastase (NE), IL-8 and TGF-β1 in the expressed prostatic secretion (EPS) of the patients.
METHODS:
We selected 120 patients with type ⅢA chronic prostatitis and randomly assigned them to medication with Huang'e Capsules (the trial group, n = 60) or Levofloxacin and Tamsulosin (the control group, n = 60), both for a course of 4 weeks. We obtained the NIH-CPSI scores and the levels of NE, IL-8 and TGF-β1 in the EPS, and compared them between the two groups before and after treatment.
RESULTS:
Totally, 116 of the patients completed the study, 59 in the trial and 57 in the control group. The overall clinical effectiveness was significantly higher in the trial group than in the control (89.8% vs 77.2%, P<0.05). Compared with the baseline, the patients of the trial group showed significant decreases after treatment in the total NIH-CPSI scores (32.5±7.4 vs 13.2±5.1), pain symptom scores (13.7±3.9 vs 4.2±2.3), urination symptom scores (6.9±2.4 vs 5.1±3.2) and quality of life (QOL) scores (8.3±2.7 vs 3.7±1.5) (all P< 0.05), and so did the controls in the total NIH-CPSI scores (30.8±7.8 vs 13.7±3.9), pain symptom scores (14.2±4.1 vs 7.8±2.9), urination symptom scores (7.1±2.7 vs 4.9±3.4) and quality of life (QOL) scores (8.1±2.4 vs 5.6±1.9) (all P< 0.05), and the decreases were even more significant in the trial than in the control group in the pain symptom and QOL scores ( P< 0.05). The patients of the trial group also exhibited a marked reduction after treatment in the contents of NE ([1135.4±321.5] vs [347.6±207.3] ng/L, P< 0.05) and IL-8 ([974.9±231.6] vs [ 431.3±207.2] ng/L, P< 0.05) but an elevation in that of TGF-β1 ([591.0±172.1] vs [1 402.1 ± 221.5] ng/L, P< 0.05) in the EPS, and so did the controls in the levels of NE ([1052.8±280.3] vs [761.1±225.1] ng/L, P<0.05), ([1007.5±287.7] vs [775.7±182.5] ng/L, P< 0.05), ([607.8±201.3] vs [871.3±192.5] ng/L, P< 0.05), with even more significant improvement in the trial than in the control group (P< 0.05).
CONCLUSION
Huang'e Capsules has a significant clinical efficacy and safety in the treatment of type IIIA prostatitis, which can effectively relieve the pain and urination symptoms and improve the levels of the inflammatory cytokines NE, IL-8 and TGF-β1 in the patients.
Humans
;
Male
;
Prostatitis/metabolism*
;
Interleukin-8/metabolism*
;
Drugs, Chinese Herbal/therapeutic use*
;
Transforming Growth Factor beta1/metabolism*
;
Prostate/metabolism*
;
Leukocyte Elastase/metabolism*
;
Tamsulosin
;
Treatment Outcome
;
Capsules
;
Middle Aged
;
Phytotherapy
;
Cytokines/metabolism*
;
Adult
;
Levofloxacin
3.Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice.
Xiaoqing FAN ; Chutian MAI ; Ling ZUO ; Jumin HUANG ; Chun XIE ; Zebo JIANG ; Runze LI ; Xiaojun YAO ; Xingxing FAN ; Qibiao WU ; Peiyu YAN ; Liang LIU ; Jianxin CHEN ; Ying XIE ; Elaine Lai-Han LEUNG
Acta Pharmaceutica Sinica B 2023;13(3):1164-1179
Sepsis-induced liver injury (SILI) is an important cause of septicemia deaths. BaWeiBaiDuSan (BWBDS) was extracted from a formula of Panax ginseng C. A. Meyer, Lilium brownie F. E. Brown ex Miellez var. viridulum Baker, Polygonatum sibiricum Delar. ex Redoute, Lonicera japonica Thunb., Hippophae rhamnoides Linn., Amygdalus Communis Vas, Platycodon grandiflorus (Jacq.) A. DC., and Cortex Phelloderdri. Herein, we investigated whether the BWBDS treatment could reverse SILI by the mechanism of modulating gut microbiota. BWBDS protected mice against SILI, which was associated with promoting macrophage anti-inflammatory activity and enhancing intestinal integrity. BWBDS selectively promoted the growth of Lactobacillus johnsonii (L. johnsonii) in cecal ligation and puncture treated mice. Fecal microbiota transplantation treatment indicated that gut bacteria correlated with sepsis and was required for BWBDS anti-sepsis effects. Notably, L. johnsonii significantly reduced SILI by promoting macrophage anti-inflammatory activity, increasing interleukin-10+ M2 macrophage production and enhancing intestinal integrity. Furthermore, heat inactivation L. johnsonii (HI-L. johnsonii) treatment promoted macrophage anti-inflammatory activity and alleviated SILI. Our findings revealed BWBDS and gut microbiota L. johnsonii as novel prebiotic and probiotic that may be used to treat SILI. The potential underlying mechanism was at least in part, via L. johnsonii-dependent immune regulation and interleukin-10+ M2 macrophage production.
4.Erratum: Author correction to 'Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice' Acta Pharmaceutica Sinica B 13 (2023) 1164-1179.
Xiaoqing FAN ; Chutian MAI ; Ling ZUO ; Jumin HUANG ; Chun XIE ; Zebo JIANG ; Runze LI ; Xiaojun YAO ; Xingxing FAN ; Qibiao WU ; Peiyu YAN ; Liang LIU ; Jianxin CHEN ; Ying XIE ; Elaine LAI-HAN LEUNG
Acta Pharmaceutica Sinica B 2023;13(8):3575-3576
[This corrects the article DOI: 10.1016/j.apsb.2022.10.016.].
5.Automated diagnostic classification with lateral cephalograms based on deep learning network model.
Qiao CHANG ; Shao Feng WANG ; Fei Fei ZUO ; Fan WANG ; Bei Wen GONG ; Ya Jie WANG ; Xian Ju XIE
Chinese Journal of Stomatology 2023;58(6):547-553
Objective: To establish a comprehensive diagnostic classification model of lateral cephalograms based on artificial intelligence (AI) to provide reference for orthodontic diagnosis. Methods: A total of 2 894 lateral cephalograms were collected in Department of Orthodontics, Capital Medical University School of Stomatology from January 2015 to December 2021 to construct a data set, including 1 351 males and 1 543 females with a mean age of (26.4± 7.4) years. Firstly, 2 orthodontists (with 5 and 8 years of orthodontic experience, respectively) performed manual annotation and calculated measurement for primary classification, and then 2 senior orthodontists (with more than 20 years of orthodontic experience) verified the 8 diagnostic classifications including skeletal and dental indices. The data were randomly divided into training, validation, and test sets in the ratio of 7∶2∶1. The open source DenseNet121 was used to construct the model. The performance of the model was evaluated by classification accuracy, precision rate, sensitivity, specificity and area under the curve (AUC). Visualization of model regions of interest through class activation heatmaps. Results: The automatic classification model of lateral cephalograms was successfully established. It took 0.012 s on average to make 8 diagnoses on a lateral cephalogram. The accuracy of 5 classifications was 80%-90%, including sagittal and vertical skeletal facial pattern, mandibular growth, inclination of upper incisors, and protrusion of lower incisors. The acuracy rate of 3 classifications was 70%-80%, including maxillary growth, inclination of lower incisors and protrusion of upper incisors. The average AUC of each classification was ≥0.90. The class activation heat map of successfully classified lateral cephalograms showed that the AI model activation regions were distributed in the relevant structural regions. Conclusions: In this study, an automatic classification model for lateral cephalograms was established based on the DenseNet121 to achieve rapid classification of eight commonly used clinical diagnostic items.
Male
;
Female
;
Humans
;
Young Adult
;
Adult
;
Artificial Intelligence
;
Deep Learning
;
Cephalometry
;
Maxilla
;
Mandible/diagnostic imaging*
6.Integration of internet health and "Healthy China" strategy
Hong-bin XIE ; Shou-huo JIANG ; Wen BEI ; Yi-ming XU ; Xin-yi SUN ; Zuo-fan XIE ; Wei LU
Shanghai Journal of Preventive Medicine 2021;33(8):659-663
In the fifth scientific and technological revolution, information technology is the first productivity, which has a great impact on the supply and demand of medical services. Generally, internet medicine is equivalent to the combination between health industry and information technology. "Healthy China" strategy is China's "priority development strategy", which adheres to the principle of health equity, emphasizes the integration of health into all policies, and takes co-construction and sharing as the basic path. With implementing internet medicine, "Healthy China" strategy promotes the mobility of medical service with three tools: interconnection, data and artificial intelligence. This enhances the operation efficiency of overall medical and health system, and optimizes the allocation of medical resources. The future development of internet medicine follows the double helix mode driven by technology and policy, and the policy determines the development boundary of the industry. On the basis to ensure medical safety, we should explore the possibility of internet diagnosis and treatment further, and pay attention to the fairness of resource allocation while improving efficiency, so as to realize the co-construction and sharing of health services.
7.Current situation and prospect of internet medicine development
Shou-huo JIANG ; Hong-bin XIE ; Wen BEI ; Yi-ming XU ; Xin-yi SUN ; Zuo-fan XIE ; Wei LU
Shanghai Journal of Preventive Medicine 2021;33(8):664-671
Internet medicine is not a concept of jurisprudence. China's current medical law system mainly focuses on main qualifications of the participants who conduct diagnosis and treatment. This paper focuses on several business models of the core element (diagnosis and treatment) in internet medicine, namely: online health consultation provided by internet medical platform, online diagnosis and treatment by internet hospital, and certain artificial intelligence(AI) medicine products that are specialized for diagnosis and treatment. This paper summarizes the development of these three business models, and analyzes the main problems in their development, including the legitimacy identification of online consultation, the dilemma of the development of internet hospitals, the impact of insufficient sample data on the development of medical AI, and the reverse restriction of regulatory difficulties to the development of internet medicine. The next step of developing internet medicine is to broaden the scope of internet diagnosis and treatment on the premise of medical safety, which will be based on the improvement of current regulatory system. It is urgent to build early risk warning system and supervision/ management mechanism for internet medicine.
8.Risk analysis of internet medicine regulation
Shou-huo JIANG ; Hong-bin XIE ; Wen BEI ; Yi-ming XU ; Xin-yi SUN ; Zuo-fan XIE ; Wei LU
Shanghai Journal of Preventive Medicine 2021;33(8):672-677
The penetration and integration of internet with medical industry is apparently falling behind its interaction with other industries in terms of speed and scale. The main reason is due to the high risk and difficult supervision of internet medicine. Based on the regulatory context, this paper analyzes the endogenous and exogenous risk of internet medicine. The inherent characteristics of the internet (such as openness, diversity, multi subjectivity, virtuality, transparency, and high aggregation) lead to endogenous risks, including jurisdiction disputes, uncertainty of rights and obligations, security of personal information and medical information, monopoly. The lag of specific law in internet medicine, the lack of extensibility and synergy of traditional hierarchical regulatory system, the uncertainty of internet hospital regulatory policy details, the lack of technical specifications/operating procedures and other external system coverage in internet diagnosis and treatment lead to regulatory blind areas and exogenous risks. Based on the risk analysis, this paper discusses further construction of the mechanisms of risk assessment and regulation for internet medicine.
9.Path analysis of internet medicine supervision and management
Hong-bin XIE ; Shou-huo JIANG ; Wen BEI ; Yi-ming XU ; Xin-yi SUN ; Zuo-fan XIE ; Wei LU
Shanghai Journal of Preventive Medicine 2021;33(8):678-681
As a new form of medical industry, internet medicine has not only the endogenous risk of internet industry, but also the blind area and exogenous risk because of lagging regulation. With the continuous progress of internet information technology, online diagnosis and treatment will gradually integrate and reconstruct the traditional medical service. In the history of medical development, the emergence of new technologies generally has the characteristics of risk. Therefore, the supervision of internet medicine should adhere to the rule of inclusiveness and prudence, and take into account the cultivation of the market and standardized development. It should also build a regulatory community, coordinate governance from the four dimensions of legitimacy, compliance, rationality and superiority. Taking the law as the bottom line, we should make full use of early online warning monitoring, off-site supervision, online supervision, reputation mechanism and other measures to promote the innovative development of internet medicine under the framework of legal compliance.
10.Incidence of neonatal asphyxia and contributing factors for the develpment of severe asphyxia in Hubei Enshi Tujia and Miao Autonomous Prefecture: a multicenter study.
Su-Ying WU ; Fen PENG ; Ting DING ; Hong-Yan TAN ; Qian WU ; Xin-Qiao YU ; Zhi-Ping PAN ; Hong-Ling XIE ; Hong XIA ; Bao-Min FEI ; Kai-Dian LIU ; Zuo-Fen YUAN ; Cong-Rong TAN ; Lang JIANG ; Song-Hua ZHANG ; Qiong YI ; Wei-Hua WU ; Lin-Lin LUO ; Chang-Tao SHEN ; Jin-Fan ZHANG ; Zhen-Ju HUANG ; Shi-Wen XIA
Chinese Journal of Contemporary Pediatrics 2019;21(1):6-10
OBJECTIVE:
To investigate the incidence of neonatal asphyxia and possible contributing factors for the development of severe asphyxia in Hubei Enshi Tujia and Miao Autonomous Prefecture, China.
METHODS:
A total of 16 hospitals in Hubei Enshi Tujia and Miao Autonomous Prefecture were selected as research centers. A retrospective analysis was performed for the clinical data of 22 294 live births in these 16 hospitals from January to December, 2016 to investigate the incidence rate of neonatal asphyxia and possible contributing factors for the development of severe asphyxia.
RESULTS:
Of the 22 294 neonates born alive, 733 (3.29%) were diagnosed with neonatal asphyxia, among whom 627 had mild asphyxia and 106 had severe asphyxia. The neonates with low maternal education level, maternal anemia during pregnancy, chorioamnionitis, abnormal amniotic fluid, abnormal umbilical cord, placenta previa, placental abruption, Tujia Minority, preterm birth, and low birth weight had a higher incidence of severe asphyxia (P<0.05).
CONCLUSIONS
The incidence rate of neonatal asphyxia in Hubei Enshi Tujia and Miao Autonomous Prefecture is higher. Low maternal education level, maternal anemia during pregnancy, chorioamnionitis, abnormal amniotic fluid, abnormal umbilical cord, placenta previa, placental abruption, Tujia Minority, preterm birth, and low birth weight may be related to the development of severe neonatal asphyxia.
Asphyxia Neonatorum
;
epidemiology
;
China
;
Humans
;
Incidence
;
Infant, Newborn
;
Retrospective Studies


Result Analysis
Print
Save
E-mail